Cargando…
Exploring neurologists’ perspectives on the return of next generation sequencing results to their patients: a needed step in the development of guidelines
BACKGROUND: The use of Next Generation Sequencing such as Whole Genome Sequencing (WGS) is a promising step towards a better understanding and treatment of neurological diseases. WGS can result into unexpected information (incidental findings, IFs), and information with uncertain clinical significan...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162934/ https://www.ncbi.nlm.nih.gov/pubmed/30268121 http://dx.doi.org/10.1186/s12910-018-0320-3 |
_version_ | 1783359255960616960 |
---|---|
author | Hurlimann, Thierry Jaitovich Groisman, Iris Godard, Béatrice |
author_facet | Hurlimann, Thierry Jaitovich Groisman, Iris Godard, Béatrice |
author_sort | Hurlimann, Thierry |
collection | PubMed |
description | BACKGROUND: The use of Next Generation Sequencing such as Whole Genome Sequencing (WGS) is a promising step towards a better understanding and treatment of neurological diseases. WGS can result into unexpected information (incidental findings, IFs), and information with uncertain clinical significance. In the context of a Genome Canada project on ‘Personalized Medicine in the Treatment of Epilepsy’, we intended to address these challenges surveying neurologists’ opinions about the type of results that should be returned, and their professional responsibility toward recontacting patients regarding new discovered mutations. METHODS: Potential participants were contacted through professional organizations or direct invitations. RESULTS: A total of 204 neurologists were recruited. Fifty nine percent indicated that to be conveyed, WGS results should have a demonstrated clinical utility for diagnosis, prognosis or treatment. Yet, 41% deemed appropriate to return results without clinical utility, when they could impact patients’ reproductive decisions, or on patients’ request. Current use of targeted genetic testing and age of patients influenced respondents’ answers. Respondents stated that analysis of genomics data resulting from WGS should be limited to the genes likely to be relevant for the patient’s specific medical condition (69%), so as to limit IFs. Respondents felt responsible to recontact patients and inform them about newly discovered mutations related to the medical condition that triggered the test (75%) for as long as they are following up on the patient (55%). Finally, 53.5% of the respondents felt responsible to recontact and inform patients of clinically significant, newly discovered IFs. CONCLUSION: Our results show the importance of formulating professional guidelines sensitive to the various – and sometimes opposite – viewpoints that may prevail within a same community of practice, as well as flexible so as to be attuned to the characteristics of the neurological conditions that triggered a WGS. |
format | Online Article Text |
id | pubmed-6162934 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61629342018-10-04 Exploring neurologists’ perspectives on the return of next generation sequencing results to their patients: a needed step in the development of guidelines Hurlimann, Thierry Jaitovich Groisman, Iris Godard, Béatrice BMC Med Ethics Research Article BACKGROUND: The use of Next Generation Sequencing such as Whole Genome Sequencing (WGS) is a promising step towards a better understanding and treatment of neurological diseases. WGS can result into unexpected information (incidental findings, IFs), and information with uncertain clinical significance. In the context of a Genome Canada project on ‘Personalized Medicine in the Treatment of Epilepsy’, we intended to address these challenges surveying neurologists’ opinions about the type of results that should be returned, and their professional responsibility toward recontacting patients regarding new discovered mutations. METHODS: Potential participants were contacted through professional organizations or direct invitations. RESULTS: A total of 204 neurologists were recruited. Fifty nine percent indicated that to be conveyed, WGS results should have a demonstrated clinical utility for diagnosis, prognosis or treatment. Yet, 41% deemed appropriate to return results without clinical utility, when they could impact patients’ reproductive decisions, or on patients’ request. Current use of targeted genetic testing and age of patients influenced respondents’ answers. Respondents stated that analysis of genomics data resulting from WGS should be limited to the genes likely to be relevant for the patient’s specific medical condition (69%), so as to limit IFs. Respondents felt responsible to recontact patients and inform them about newly discovered mutations related to the medical condition that triggered the test (75%) for as long as they are following up on the patient (55%). Finally, 53.5% of the respondents felt responsible to recontact and inform patients of clinically significant, newly discovered IFs. CONCLUSION: Our results show the importance of formulating professional guidelines sensitive to the various – and sometimes opposite – viewpoints that may prevail within a same community of practice, as well as flexible so as to be attuned to the characteristics of the neurological conditions that triggered a WGS. BioMed Central 2018-09-29 /pmc/articles/PMC6162934/ /pubmed/30268121 http://dx.doi.org/10.1186/s12910-018-0320-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Hurlimann, Thierry Jaitovich Groisman, Iris Godard, Béatrice Exploring neurologists’ perspectives on the return of next generation sequencing results to their patients: a needed step in the development of guidelines |
title | Exploring neurologists’ perspectives on the return of next generation sequencing results to their patients: a needed step in the development of guidelines |
title_full | Exploring neurologists’ perspectives on the return of next generation sequencing results to their patients: a needed step in the development of guidelines |
title_fullStr | Exploring neurologists’ perspectives on the return of next generation sequencing results to their patients: a needed step in the development of guidelines |
title_full_unstemmed | Exploring neurologists’ perspectives on the return of next generation sequencing results to their patients: a needed step in the development of guidelines |
title_short | Exploring neurologists’ perspectives on the return of next generation sequencing results to their patients: a needed step in the development of guidelines |
title_sort | exploring neurologists’ perspectives on the return of next generation sequencing results to their patients: a needed step in the development of guidelines |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162934/ https://www.ncbi.nlm.nih.gov/pubmed/30268121 http://dx.doi.org/10.1186/s12910-018-0320-3 |
work_keys_str_mv | AT hurlimannthierry exploringneurologistsperspectivesonthereturnofnextgenerationsequencingresultstotheirpatientsaneededstepinthedevelopmentofguidelines AT jaitovichgroismaniris exploringneurologistsperspectivesonthereturnofnextgenerationsequencingresultstotheirpatientsaneededstepinthedevelopmentofguidelines AT godardbeatrice exploringneurologistsperspectivesonthereturnofnextgenerationsequencingresultstotheirpatientsaneededstepinthedevelopmentofguidelines |